Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1997-05-02
1999-09-07
Degen, Nancy
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
435 911, A61K 9127, C12P 1934
Patent
active
059484357
ABSTRACT:
A method of regulating cholesterol related genes, enzymes and other compounds, pharmaceutical compositions and a kit related thereto are provided. Exemplary genes that are regulated include a gene for an LDL receptor, a gene for HMG-CoA reductase, a gene for cholesterol 7-alpha-hydroxylase, and a gene regulating a function involved in cholesterol homeostasis. The method comprises the step of parenterally administering a therapeutically effective amount of a lipid acceptor. The lipid acceptor in one variant includes a multiplicity of large liposomes comprised of phospholipids substantially free of sterol during a treatment period. The method includes the steps of periodically assaying plasma LDL concentrations with an assay during a period of time to assess the plasma LDL and to obtain an LDL profile, and adjusting the parenteral administration in response to the LDL profile. The method further includes the step of enhancing tissue penetration of a cholesterol acceptor and enhancing extraction of tissue cholesterol and other exchangeable material with co-administration of an effective amount of a compound selected from the group consisting of a small acceptor of cholesterol, an amphipathic compound, and a drug that increases endogenous small acceptors of cholesterol.
REFERENCES:
patent: 4812314 (1989-03-01), Barenholz et al.
patent: 5077056 (1991-12-01), Bally et al.
patent: 5204112 (1993-04-01), Hope et al.
patent: 5252263 (1993-10-01), Hope et al.
patent: 5376452 (1994-12-01), Hope et al.
patent: 5489611 (1996-02-01), Lee et al.
patent: 5556637 (1996-09-01), Hager et al.
patent: 5622715 (1997-04-01), Barenholz et al.
patent: 5736157 (1998-04-01), Williams
patent: 5741514 (1998-04-01), Barenholz et al.
patent: 5741517 (1998-04-01), Hager et al.
Daida et al., Prevention Of Restenosis After Percutaneous Transluminal Coronary Angioplasty By Reducing Lipoprotein (a) Levels With Low-Density Lipoprotein Apheresis, Jun. 1, 1994, vol. 73, No. 15, pp. 1037-1040.
Desmarais et al., Elevated Serum Lipoprotein(a) Is A Risk Factor For Clinical Recurrence After Coronary Balloon Angioplasty, Circulation, vol. 91, No. 5, Mar. 1, 1995, pp. 1403-1409.
Groop et al., Lipoprotein(a) In Type 1 Diabetic Patients With Renal Disease, Original Articles, May 11, 1994, pp. 961-967.
Kokuglu et al., Elevated Serum Lp(a) Levels In The Early And Advanced Stages Of Breast Cancer, Cancer Biochem, Biophys., 1994, vol. 14, pp. 133-136.
Kuriyama et al., Low Levels Of Serum Apolipoprotein A I and II In Senile Dementia, The Japanese Journal Of Psychiatry And Neurology, vol. 48, No. 3, 1994, pp. 589-593.
Sachs, Bernard A., et al., In Vivo Effects Of Inositol Phosphatide (Lipositol) In Serum Lipids And Atherosclerosis Of Hyperlipemic Rabbits, J. Appl. Physiol., 15:983-986, 1960.
Takahashi et al., Increased Concentrations Of Serum Lp(a) Lipoprotein In Patients With Primary Gout, Annals Of The Rheumatic Diseases 1995, vol. 54, pp. 90-93.
Tenda et al., The Relationship Between Serum Lipoprotein(a) And Restenosis After Initial Elective Percutaneous Transluminal Coronary Angioplasty, Japanese Circulation Journal, vol. 57, Aug., 1993, pp. 789-795.
Williams et al., Uptake of Endogenous Cholesterol By A Synthetic Lipoprotein, Elsevier Science Publishers B.V. (Biomedical Division), 1986, pp. 183-194.
Yamamoto et al., Serum Lipoprotein (a) Levels Before And After Subtotal Thyroidectomy In Subjects With Hyperthyroidism, Metabolism, vol. 44, No. 1 (Jan.), 1995, pp. 4-7.
Adams CWM, Abdulla YH, Bayliss OB, Morgan RS: Modification of aortic atheroma and fatty liver in cholesterol-fed rabbits by intravenous injection of saturates and polyunsaturated lecithins. J Pathol Bacteriol 94:77-87, 1967.
Altman RFA, de Mendonia JM, Schaeffer GMV, Ramos de Souza J, Bandoli JG, da Silva DJ, Lopes CRN: Phospholipids in experimental atherosclerosis. Arzneim Forsch 24:11-16, 1974.
Aviram M, Williams KJ, Deckelbaum RJ: Macrophage cholesterol removal by triglyceride-phospholipid emulsions. Biochem Biophys Res Commun 155:709-713, 1988.
Aviram M, Williams KJ, McIntosh RA, Carpentier YA, Tall AR, Deckelbaum RJ: Intralipid infusion abolishes ability of human serum to cholesterol-load cultured macrophages. Arteriosclerosis 9:67-75, 1989.
Bally MB, Hope MJ, Mayer LD, Madden TD, Cullis PR: Novel procedures for generating and loading liposomal systems. In: Gregoriadis G, ed. Liposomes as drug carriers: recent trends and progress. Chichester, England: John Wiley & Sons Ltd., 1988. pp. 841-853.
Bialecki RA, Tulenko TN, Colucci WS: Cholesterol enrichment increases basal and agonist-stimulated calcium influx in rat vascular smooth muscle cells. J Clin Invest 88:1894-1900, 1991.
Blaton V, Declercq B, Vandamme D, Soetewey F, Peeters H: The human plasma lipids and lipoproteins under influence of EPL-therapy. In: Peeters H, ed. Phosphatidylcholine. Berlin: Springer-Verlag, 1976. pp. 125-132.
Byers SO, Friedman M: Effect of infusions of phosphatides upon the atherosclerotic aorta in situ and as an ocular aortic implant. J Lipid Res 1:343-348, 1960.
Campanacci L, Guarnieri G, Faccini L, Bellini G: Response of plasma lipid fractions to the administration of exogenous phospholipids. Arzneimittelforschung 25:1306-1308, 1975.
Ciammaichella A, Solitro A, Arcuri P: La fosfatidilcolina polinsatura (EPL) nel trattamento delle affezioni aterosclerotiche cerebrali e degli arti inferiori. Clin Ter 74:55-62, 1975.
Ellens H, Morselt H, Scherphof G: In vivo fate of large unilamellar sphingomyelin-cholesterol liposomes after intraperitoneal and intravenous injection into rats. Biochim Biophys Acta 674:10-18, 1981.
Friedman M, Byers SO, Rosenman RH: Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion. Proc Soc Exp Biol Med 95:586-588, 19with L,D. alpha (dimyristoyl) lecithin. J Lab Clin Med 56:30-37, 1960.
Howard AN, Patelski J, Bowyer DE, Gresham GA: Atherosclerosis induced in hypercholesterolaemic baboons by immunological injury; and the effects of intravenous polyunsaturated phosphatidyl choline. Atherosclerosis 14:17-29, 1971.
Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW: Effect of pravastatin on outcomes after cardiac transplantation. New Engl J Med 333:621-627, 1995.
Krack G, Viglino G, Cavalli PL, Gandolfo C, Magliano G, Cantaluppi A, Peluso F: Intraperitoneal administration of phosphatidylcholine improves ultrafiltration in continous ambulatory peritoneal dialysis patients. Perit Dial Int 12:359-364, 1992.
Mauk MR, Gamble RC: Stability of lipid vesicles in tissues of the mouse: a gamma-ray perturbed angular correlation study. Proc Natl Acad Sci (USA) 76:765-769, 1979.
Maurukas J, Thomas RG: Treatment of experimental atheroslerosis in the rabbit with L, D. alpha (dimyristoyl) lecithin. J Lab Clin Med 56:30-37, 1960.
Mihail A, Popescu P, Idu SM, Petrescu X, Cociumian L, Mihai N: The coronary syndrome in two cases of essential familial hypercholesterolemia (the therapeutic effect of polyene-phosphatidyl-choline). Rev Roum Med Intern 10:225-233, 1973.
Miyazaki A, Sakai M, Suginohara Y, Hakamata H, Sakamoto Y, Morikawa W, Horiuchi S: Acetylated low density lipoprotein reduces its ligand activity for the scavenger receptor after interaction with reconstituted high density lipoprotein. J Biol Chem 269:5264-5269, 1994.
Patelski J, Bowyer DE, Howard AN, Jennings IW, Thorne CJR, Gresham GA: Modification of enzyme activities in experimental atherosclerosis in the rabbit. Atherosclerosis 12:41-53, 1970.
Plane F, Bruckdorfer KR, Kerr P, Steuer A, Jacobs M: Oxidative modification of low-density lipoproteins and the inhibition of relaxations mediated by endothelium-derived nitric oxide in rabbit aorta. Br J Pharmacol 105:216-222, 1992.
Rodrigueza WV, Hope MJ, Williams KJ: Large unilamellar vesicles (LUV) efficiently mobilize tissue cholesterol to live yet do not provoke a rise in plasma concentrations of cholesteryl ester-rich atherogenic lipoprotein. 18th Canadian Lipoprotein Conference Oct. 17: 1994 (Abst
Degen Nancy
Talaria Therapeutics, Inc.
LandOfFree
Methods of regulating CETP genes, enzymes and other compound, an does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of regulating CETP genes, enzymes and other compound, an, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of regulating CETP genes, enzymes and other compound, an will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1802308